However, preservation of hypothalamic GUCY2C in DIO suggests the feasibility of a therapeutic paradigm involving cognate ligand replacement to manage obesity and its comorbidities. Here, GUCY2C is linked to obesity due to melanocortin 4 receptor deficiency.